Phase II Pantiumumab-IRDye800 in Head & Neck Cancer
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying
cancer, compared to surrounding normal tissue, and the further characterize the safety
profile of this drug.